Studies done exclusively in patients of a single race or ethnicity and studies reporting effect modifications by baseline urine protein level were annotated. Studies were also Table 9 | Work products for BP guideline* Topic Summary table of RCTs Evidence profile Diet or lifestyle modification Exercise + (single study) BP targets in CKD without DM BP target in adults + + (3 studies) BP target in children + (single study) Adverse events of target RCTs + a Agents in CKD without DM, non-transplant ACE-I or ARB versus CCB + + (7 studies) ACE-I or ARB versus placebo + + (6 studies) High-dose ACE-I versus low-dose ACE-I + + (2 studies) ACE-I versus ARB + + (3 studies) ACE-I versus beta-blocker + (single study) High-dose ARB versus low-dose ARB + + (3 studies) (ACE-I + CCB) versus ACE-I + (single study) (ACE-I + CCB) versus CCB + (single study) Beta-blocker versus CCB + (single study) CCB versus CCB + (single study) Central-acting agent versus CCB + (single study) Adverse events of agent RCTs + a Agents in CKD with DM, non-transplant Aldosterone antagonist versus placebo + (single study) ACE-I or ARB versus CCB + + (7 studies) ACE-I or ARB versus placebo + + (9 studies) ACE-I versus ARB + + (3 studies) ARB versus ARB + + (3 studies) CCB versus placebo + (single study) Direct renin inhibitor versus placebo + (single study) Endothelin antagonist versus endothelin antagonist + (single study) Endothelin antagonist versus placebo + (single study) Adverse events of agents in RCTs + a Agents in CKD in kidney transplant recipient ACE-I versus ARB + (single study) ARB versus placebo + (single study) ACE-I versus CCB + + (2 studies) CCB versus placebo + + (3 studies) Adverse events of agent RCTs + a CKD subgroups from general population studies BP target + (1 study) ACE-I + diuretic versus placebo in DM + (4 studies) ACE-I or ARB versus control + (5 studies) ACE + ARB or ARB versus ACE-I + (1 study) ARB versus CCB + (1 study) CCB versus control + (2 studies) ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin-receptor blocker; BP, blood pressure; CCB, calcium-channel blocker; CKD, chronic kidney disease; DM, diabetes mellitus; RCTs, randomized controlled trials; +, work product is indicated for the topic of interest; , work product is not indicated for the topic of interest. 